#Top Ten Pharma Companies

[telugutimesdigimedia]

American company invests Rs.800 crores in Telangana

The Telangana government has entered into an MoU with Bristol Meyers, an American pharma company. The agreement was signed by the representatives of the Bristol Mayors organization under the leadership of the Minister of State for IT and Industries KTR. The minister said that 1500 people will get employment opportunities through this company which has come forward with an investment of more than Rs.800 crores. On this occasion, Bristol Mayors explained to the representatives of the organization that the world's largest pharma cluster is being established in Hyderabad.

[irenepharma]

Best PCD Pharma Franchise Company in India

Irene Pharma is a leading and fastest-growing PCD Pharma Franchise Company in India. PCD stands for Propaganda-Cum-Distribution and is utilized in the pharmaceutical sector to enable pharma manufacturing, marketing, and distribution. We are pleased to be one of India's best PCD pharma franchise service providers. We believe that only a healthy life can lead to a dynamic future and this approach inspired us to begin building reliable connections to serve society with our pharma products. We have already built a vast network of franchise associates.

The PCD Pharma franchise is one of the most popular businesses in India. The pharma sector is among the most flourishing and promising ones. And since there are many business models, you have various choices to make profits. If you ask industry experts, then launching a pharma franchise company could be a great choice.

Irene Pharma is one of the best pharma companies in India dealing in high-quality pharma medicines. We offer an exclusive range of high-quality healthcare products and pharma items that covers all medical therapeutic segments. Our professional and quality services make us India's most trusted Pharma Franchise Company.

Visit our Website: https://irenepharma.com/

[undreaming-fanfiction]

I don't even have a clear storyline in mind for this, but I just really, really want to see a modern AU with Eddie as a detective who investigates the Harrington Pharma company. The company is huge and looks clean on paper, but Eddie has a nose for these things, he knows something is wrong. He knows that Richard Harrington ran some sketchy trials and some of Wayne's friends have lifelong health issues, Chief Jim Hopper included.

The company looks almost impenetrable, but Eddie digs. No detail is too small for him. He crosses paths with the owner's son and a board member, Steve Harrington. Eddie despises him. A fucking rich kid, making millions out of other people's misery. His public appearances are well rehearsed, but Eddie knows his type. A shallow, pretty partying douchebag who hasn't had to work a single day in his life. His PR manager Robin Buckley seems way too decent to work with such a bunch of assholes, but Eddie's seen what money can do to people. Either way she's corrupt too.

He meets the younger Harrington several times. The handsome young man is not openly hostile, but he's condescending, bitchy and he looks at Eddie as if he were dirt. "Good luck with your efforts," he sneers when he sees Eddie digging through the public records of Harrington Pharma. "But maybe get a real hobby instead? I hear golf is nice." Eddie wants to murder him.

Eddie cooperates with an investigative journalist, Nancy Wheeler, who keeps all her cards close to her chest, but she still points him in the right direction several times. He collects evidence, partners up with the public prosecutor Joyce Byers. He even meets her son, Jonathan, who is able to get the most damning photographic evidence. No one fully trusts each other, but that's okay. Harrington Pharma is their shared enemy and that's enough.

One day, Eddie makes a mistake. He sneaks into the Harrington Pharma archives and miscalculates the guard shifts. He's stuck hiding under an old desk for hours, he's slowly losing hope, he has no way to contact anyone, his legs are cramping and he's exhausted, but then he hears a familiar voice talking with the guard.

"Hi, Tommy. All good? How's Carol and the kids? That's wonderful to hear. I just need to verify some records for dad, it's not a big deal. Have you had your smoke break yet? You can go, stretch your legs. I'll be here for at least half an hour."

Shit. It's Steve fucking Harrington. Eddie tries to stay still and will his muscles to cooperate, and he thinks he's doing a great job, but then-

"You can come out now. He's gone."

Eddie freezes. How the fuck does he know?

Harrington's voice is quiet, urgent. "Damn it, Munson! You have ten minutes tops before he comes back, so stop playing hide and seek with me!"

He manages to get back on his feet, uncertain and wobbly, and when he sees Harrington leaning over the desk, he's half ready for a fight. But the other man doesn't make a move, doesn't call out to anyone. He just hands Eddie a folder, some of them are the files he selected, but some are new. "I added a few that you missed," hisses Harrington and leans into the corridor. "I'll go first, get Tommy to focus somewhere else. You run to the right and pray to anyone willing to listen. And most importantly," he says, and shit, Steve Harrington can sound serious if he wants to!, "I never saw you here. You heard me come in, used the opportunity and bolted. Clear?"

Eddie just nods. He watches as Steve extends his arm, probably grabbing Tommy by the shoulders and leading him to the other end of the building, he sneaks as far as he can and then he madly dashes for the hole in the fence he made earlier.

The files are it. With all the evidence Nancy, Jonathan and Eddie collected, Joyce can finally take that dark empire down. Eddie is there every day, watches the trial, but then he hears that there are two witnesses for the prosecution from inside the company itself.

It's Steve Harrington and Robin Buckley.

He sees Steve give him a wink from the stand and he wants to kiss the man. Eddie hears all of it in the following days - how Steve used to date Nancy Wheeler, but then her best friend Barb Holland died due to a mishandled drug trial for her condition by Harrington Pharma. How Nancy broke up with Steve, but even with no chance of rekindling their relationship, he vowed to stop his father for good. How he worked in the company for years, climbed the ladder, managed to make enough connections to get his friend Robin Buckley the position of a PR manager. How she helped him to keep up the charade until the very end.

When the Harrington empire finally falls, Eddie watches quietly as Steve embraces Nancy, whispering to her that she did so well, that Barb would be proud. "We finally did it, Nance. We're finally free."

And then, before Eddie can disappear, Harrington is walking towards him, the mask finally off. He looks younger now, his smile is genuine and Eddie can't help it, his traitorous heart is telling him that this is the single part of the Harrington case he'll never leave behind.

"Hi," says Steve. "I...uh. I just wanted to say sorry for all the nasty things I said before. I had to for my cover, but...I just want you to know, I really appreciate what you did."

Eddie just stares at him, blush forming on his cheeks and a crush blooming in his heart. "I'm pretty sure I just butchered your career," he mutters. "And you're thanking me?"

Steve shrugs. "I mean. I'm out of job, I'm a known whistleblower now and my dad's lawyers will probably try to sue me. So that's not great. But if you want to ease your conscience...take me out for a coffee?" Another wink, another squeeze around Eddie's heart.

Eddie fakes a deep sigh and takes Steve by the elbow. "I don't think a single coffee is going to get rid of all my guilt, but it's a start. Maybe a lunch tomorrow would help my healing process?"

Laughing, Steve nudges his side. "Anything for your peace of mind, Eddie."

[workersolidarity]

🌍 🏦💵 🚨

FIVE RICHEST BILLIONAIRES DOUBLE THEIR WEALTH SINCE 2020 WHILE 5 BILLION ARE MADE POORER

Oxfam International, a British-founded International Charitable organization based in Nairobi, Kenya, says the world's richest people have managed to double their wealth since 2020, as 5 billion people are made poorer as a result of a "decade of division."

Oxfam made the claims in a press release on its recently published report released Monday, January 15th on inequality and global corporate power called "Inequality Inc."

According to Oxfam, the world's richest people have more than doubled their wealth from $405 billion to $869 billion since 2020, a rate equivelent to $14 million per hour, while approximately 5 billion people have been made poorer in the same time period.

"If current trends continue," the statement says, "the world will have its first trillionaire within a decade but poverty won't be eradicated for another 229 years."

Oxfam looks to the Davos gathering of the world's largest corporations, pointing to the valuations of the top ten largest companies, together worth more than $10.2 trillion.

“We’re witnessing the beginnings of a decade of division, with billions of people shouldering the economic shockwaves of pandemic, inflation and war, while billionaires’ fortunes boom. This inequality is no accident; the billionaire class is ensuring corporations deliver more wealth to them at the expense of everyone else,” Oxfam's International interim Executive Director Amitabh Behar is quoted as saying.

“Runaway corporate and monopoly power is an inequality-generating machine: through squeezing workers, dodging tax, privatizing the state, and spurring climate breakdown, corporations are funneling endless wealth to their ultra-rich owners. But they’re also funneling power, undermining our democracies and our rights. No corporation or individual should have this much power over our economies and our lives —to be clear, nobody should have a billion dollars”.

According to Oxfam, Billionaires increased their wealth by $3.3 trillion since 2020, a growth rate three times faster than inflation.

Oxfam adds that, despite representing just 21% of the global population, the countries of the Global North own 69% of global wealth, with Global North countries home to 74% of global billionaire wealth.

Further, the top 1% own 43% of all global financial assets, with billionaires owning 48% of wealth in the Middle East, 50% in Asia, and 47% in Europe.

In addition to overall wealth, 148 of the world's largest corporations raked in $1.8 trillion in total net profits, a 52% increase over the period from 2018-2021.

Corporate windfalls increased to nearly $700 billion, with the report finding that for every $100 in profits made by the top 96 major corporations between July 2022 and June 2023, $82 was paid out to wealthy shareholders.

Oxfam International interim Executive Director Amitabh Behar says that “Monopolies harm innovation and crush workers and smaller businesses. The world hasn’t forgotten how pharma monopolies deprived millions of people of COVID-19 vaccines, creating a racist vaccine apartheid, while minting a new club of billionaires."

The Oxfam press release goes on to point our that people are working harder and for longer, often for poverty wages in unsafe jobs, adding that the wages of nearly 800 million people have not kept up with inflation, losing $1.5 trillion in value over the last two years, the equivalent of nearly a month's lost wages for each individual worker.

Oxfam also found that, of the 1'600 largest companies, less than 0.4% of them are publicly committed to paying employees a living wage.

Oxfam shows how a "war on taxation" by large corporations has pushed the effective tax rates on corporations to fall by a third in recent decades, while relentless privitization of public services like education and water services have expanded massively.

“We have the evidence. We know the history. Public power can rein in runaway corporate power and inequality —shaping the market to be fairer and free from billionaire control. Governments must intervene to break up monopolies, empower workers, tax these massive corporate profits and, crucially, invest in a new era of public goods and services,” said Behar.

“Every corporation has a responsibility to act but very few are. Governments must step up. There is action that lawmakers can learn from, from US anti-monopoly government enforcers suing Amazon in a landmark case, to the European Commission wanting Google to break up its online advertising business, and Africa’s historic fight to reshape international tax rules.”

Oxfam offers three notes on how governments can rectify the situation, including the following:

🔹 Revitalizing the state. A dynamic and effective state is the best bulwark against extreme corporate power. Governments should ensure universal provision of healthcare and education, and explore publicly-delivered goods and public options in sectors from energy to transportation.

🔹 Reining in corporate power, including by breaking up monopolies and democratizing patent rules. This also means legislating for living wages, capping CEO pay, and new taxes on the super-rich and corporations, including permanent wealth and excess profit taxes. Oxfam estimates that a wealth tax on the world’s millionaires and billionaires could generate $1.8 trillion a year.

🔹 Reinventing business. Competitive and profitable businesses don’t have to be shackled by shareholder greed. Democratically-owned businesses better equalize the proceeds of business. If just 10 percent of US businesses were employee-owned, this could double the wealth share of the poorest half of the US population, including doubling the average wealth of Black households.

#source

@WorkerSolidarityNews

[beardedmrbean]

Oct. 3 (UPI) -- Ten U.S. drug manufacturers have agreed to participate in the initial round of the first-ever pricing negotiations between Medicare and the nation's pharmaceutical giants, the Biden administration announced Tuesday.

The highly anticipated Medicare Drug Price Negotiation Program was set to enter its next phase after the Centers for Medicare & Medicaid Services invited the drugmakers to voluntarily join the program in August.

The move comes as President Joe Biden seeks to fulfill a campaign promise to make prescription medicines more affordable for millions of aging Americans.

The drugs on the list are among the most commonly used to treat everything from heart failure, blood clots, diabetes, arthritis, and Crohn's disease, however, average Americans often cannot afford to buy the drugs, Biden said in August when the drug cost reform effort kicked off.

Previously, the White House said the drugs are among the top 50 prescription medications that seniors fill the most at retail pharmacies under Medicare Part D.

The companies electing to participate include Bristol Myers Squibb, Boehringer Ingelheim, Janssen Pharmaceuticals, Merck Sharp Dohme, AstraZeneca, Novartis, Immunex, Pharmacyclics LLC, Jannsen Biotech and Novo Nordisk.

Collectively, the companies' drugs brought in $50.5 billion from prescriptions covered under Part D between June 1, 2022, and May 31, 2023, with consumers paying $3.4 billion in out-of-pocket costs, according to a statement from the Department of Health and Human Services.

"Drug companies that manufacture these drugs have indicated that they will participate in negotiations with Medicare during the remainder of 2023 and in 2024, and any agreed-upon negotiated prices will become effective beginning in 2026," the statement said.

The pricing program is being funded through the Inflation Reduction Act of 2022, which expanded Medicare's authority to negotiate out-of-pocket drug costs, including a $2 monthly cap on certain generic drugs used to treat chronic conditions, as well as a $35 price cap on insulin.

The pandemic-era legislation contains a broad range of actions to mitigate high drug prices, including a plan that adds commercial health insurers to a requirement that forces drug companies to pay rebates to Medicare whenever medicine prices rise faster than inflation.

Merck and Johnson & Johnson have filed multiple lawsuits in an effort to declare Biden's plan unconstitutional.

Biden has vowed to continue to pursue lower drug costs, arguing his pricing plan was working to help struggling Americans while the pharmaceutical industry raked in billions in record profits.

"There is no reason why Americans should be forced to pay more than any developed nation for life-saving prescriptions just to pad Big Pharma's pockets," Biden said at the time.

When the pricing negotiations conclude, the Centers for Medicare & Medicaid Services will announce the prices of the selected drugs on or before September 2024, however, the new drug prices won't go into effect until 2026.

From there, the government will select up to 15 more drugs covered under Part D for 2027, and up to 15 more drugs for 2028, including drugs covered under Part B and Part D.

The program will add up to 20 more drugs each year after that, as required by the Inflation Reduction Act.

[tritonmarketresearchamey]

India's Pharmaceutical Market: Key Trends & Drivers Explained

The Indian pharmaceutical industry is set for remarkable growth, expected to reach $65 billion by 2024 and $130 billion by 2030, up from its current $50 billion valuation, according to Invest India. As a leading exporter, India serves over 200 countries, supplying more than 50% of Africa’s generic drugs, about 40% of the United States’ generic drug demand, and 25% of the UK’s medicines. India also accounts for around 60% of global vaccine demand and provides 70% of the World Health Organization’s essential immunization vaccines, including DPT, BCG, and Measles. This expansion highlights India’s crucial role in the global healthcare sector, highlighting its robust export capabilities and significant contributions to vaccine supply.

India’s Rising Importance in The Global Pharmaceutical Landscape

India’s pharmaceutical industry sees exports accounting for over $25 billion, supplying 20% of global generic medicines demand. This growth positions India with about 13% of the global pharmaceutical market share. Also, according to the Indian Brand Equity Foundation (IBEF), the nation is the third-largest producer of active pharmaceutical ingredients (APIs), holding 8% of the global market share and manufacturing over 500 APIs.

According to the Department of Pharmaceuticals, Indian pharmaceutical firms are key players in the United States and European Union (EU) prescription drug sectors, with the highest number of FDA-approved manufacturing plants outside the US. As the world’s largest supplier of generic medicines, the nation meets 20% of global demand by volume. Globally valued at $42 billion, India’s pharmaceutical industry saw nearly 5% year-on-year growth in FY23, reaching $49.78 billion. This growth, driven by an 8% increase in exports and a 6% rise in domestic market growth from FY18 to FY23, underscores India’s role as a major pharmaceutical hub.

The sector further ranks among India’s top ten industries attracting foreign investment, with exports reaching highly regulated markets like the US, Western Europe, Japan, and Australia. During the global health crisis, India demonstrated its capability by supplying around 45 tons and 400 million hydroxychloroquine tablets to 114 countries.

Driving Forces in India’s Pharmaceutical Market

India’s pharmaceutical industry is driven by population growth, urbanization, and an increasing prevalence of chronic diseases. Rising healthcare expenditures, supported by both public and private sectors, further boost the industry growth. In this regard, government initiatives like ‘Ayushman Bharat Yojana’ significantly enhance medication accessibility.

Additionally, schemes like the Production Linked Incentive (PLI) scheme promote domestic manufacturing to reduce import dependency, while the Development of Pharmaceutical Industry (DPI) scheme enhances efficiency and competitiveness through sub-schemes for Bulk Drugs and Medical Devices. These efforts aim to elevate India’s global pharma presence and provide affordable, quality healthcare solutions. Increased investments in research and development (R&D) for new drugs further reinforce India’s significant role in global pharmaceutical innovation.

Major companies, such as Sun Pharma and Mankind, are expanding their market reach by deploying 12,000 medical representatives in urban and rural areas to engage with healthcare professionals.

Regulatory Environment & Advancing Tech in The Indian Pharmaceutical Industry

The pharmaceutical industry in India operates under stringent regulatory oversight to ensure drug safety, efficacy, and quality. The Central Drugs Standard Control Organization (CDSCO) , under the Ministry of Health & Family Welfare, controls the manufacture, import, distribution, and drug sales through the Drugs & Cosmetics Act 1940. The Drugs and Magic Remedies (Objectionable Advertisement) Act 1954 regulates drug advertising, prohibiting claims of miraculous properties.

Further, Good Clinical Practice (GCP) guidelines, developed in collaboration with the Drugs Controller General of India (DCGI) and the Indian Council for Medical Research (ICMR) , set standards for human subject research aligning with international norms like the Declaration of Helsinki and World Health Organization (WHO) guidelines. Its regulatory framework also aligns with international guidelines, including the International Conference on Harmonization (ICH) standards and regulations from bodies like the US FDA and the European Medicines Agency (EMA) , ensuring compliance with global standards.

In recent years, the Indian pharmaceutical sector has been at the forefront of technological innovation, harnessing artificial intelligence (AI), big data analytics, telemedicine, and the Internet of Medical Things (IoMT) to revolutionize healthcare delivery. PharmEasy, launched in 2015, stands as a prime example that has democratized healthcare access by seamlessly connecting patients with nearby pharmacies and diagnostic centers. Similarly, Cipla is digitizing its pharmaceutical sales approach by equipping medical representatives with iPads for e-detailing. This digital transformation enhances sales effectiveness via streamlined communication and interactive engagement with healthcare providers. This wave of innovation is supported by initiatives like the Scheme for Promotion of Research and Innovation in the Pharma MedTech Sector (PRIP) , launched in 2023.

Global Interest Supports the Indian Pharma Sector

The Indian pharmaceutical sector attracts significant foreign direct investment (FDI) due to liberalized policies, allowing up to 100% FDI for Greenfield projects and up to 74% for Brownfield ventures. Since April 2000, the sector has drawn around $22.52 billion in FDI equity inflows, supported by over 10,000 Pradhan Mantri Bhartiya Janaushadhi Kendras nationwide. Major global players such as AstraZeneca, Dr. Reddy’s, and Pfizer have heavily invested in India’s pharmaceutical industry, leveraging its manufacturing and regulatory strengths.

Hence, this sector is set for significant growth in the next decade, driven by its role in global trade and compliance with GMP standards from WHO and USFDA. As a leading producer of generics, India expects around 912% increase in medicine spending over the next five years, placing it among the top global markets. Growth will focus on chronic therapies like cardiovascular and anti-cancer treatments. Besides, pharma companies will adopt FMCG-like strategies, manage diverse channels, and leverage the influence of pharmacists and patient empowerment. Government initiatives and expanding access to low-cost generics will further support this growth.

[innonurse]

CytoReason secures $80M funding to expand AI disease models and establish US hub

- By InnoNurse Staff -

Israel-based CytoReason has secured $80 million in funding from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to expand its AI disease models and establish a US hub in Cambridge, Massachusetts.

This investment will help CytoReason enhance its disease models, grow its proprietary data, and reduce R&D timelines for partner companies. 

CytoReason's technology, used by six of the world’s top ten pharma companies, aids in making data-driven decisions in various therapeutic areas. 

The funding supports CytoReason's aim to improve pharma R&D through predictive insights and data modeling.

Header image credit: CytoReason/Business Wire (a blue filter was added)

Read more at CytoReason/Business Wire

[swastikayurvedachd]

Most Demanding Herbal Products For Ayurvedic PCD Franchise

The body and mind can get sick with different illnesses. In today's busy world, it's hard to stay healthy. That's why a lot of people have health problems like back pain, knee pain, diabetes, stress, and hormonal imbalance at a young age. Ayurveda can help cure many diseases. The top Ayurvedic company “Swastik Ayurveda” manufactures the Most Demanding Herbal Products For Ayurvedic PCD Franchise that are safe and have no side effects. We are the top company for selling Herbal products For Ayurvedic Product Franchise. We want to help the body stay healthy and in balance.

Swastik Ayurveda is one of the most trusted and recommended companies that offer Herbal products For Ayurvedic Pharma Franchise. The company offers a special variety of top-notch Herbal products for the Ayurvedic Pharma Franchise all over India. We want to reach as many people as possible with our special Ayurvedic herbal products.

Over time, the company has gained the trust of healthcare professionals and customers by consistently providing accurate and precise high-quality herbal medicine. Today, Swastik Ayurveda is the best company for selling Most Demanding Herbal Products For Ayurvedic PCD Franchise.

Herbal Products For Ayurvedic PCD Franchise

77 out of every 100 Indian homes use Ayurvedic products every day. Due to new technology and scientific knowledge, herbal medicine has improved. They are used to help with different health problems like diabetes and high blood pressure. They can also reduce swelling, improve sleeping, cleanse the body, help with weight loss, and treat skin issues.

Take a look at our most demanding herbal products for Ayurvedic PCD Franchise

Almond, Chandan & Glycerin Soap

Aloe Vera and Neem Facewash

Swastik Aloe-Vera Juice

Aloe-Vera Juice

Antacid Syrup

Glam-Mantra Cream

Ayurvedic Acne Scar Cream

Ayurvedic Antacid Tablets

Ayurvedic Anti-Diabetic Capsules

Ayurvedic Anti-Fungal Cream

Ayurvedic Antipyretic Syrup

Chyavanaprash

Ayurvedic Chyawanprash

Ayurvedic Cold Balm

Ayurvedic Cough Syrup

Swissplat Tonic

Ayurvedic Fever & Viral Syrup

Kesh-Shikha Oil

Ayurvedic Herbal Oil

Ayurvedic Immuno-modulator Malt

Ayurvedic Immunomodulator Kadha

Ayurvedic Intimate Hygiene Wash for Men

Swissplat Juice

Ayurvedic Juice for Fevers & Virals

Ayurvedic Liver Capsules

Ayurvedic Mouthwash

Ayurvedic Pain Balm

Ayurvedic Piles Capsule

Ayurvedic Piles Ointment

Ayurvedic Sex Capsule

Gyno-Hit Syrup

Ayurvedic Syrup for Women Health

Ayurvedic Toothpaste

Blood Purifier Capsule

Blood Purifier Syrup

Bowel Regulator Powder

Brain Tonic

Charcoal & Aloevera Soap

Cissus Quadrangularis Capsules

Cissus Quadrangularis Tablets

Coconut Oil & Rose Extract Soap

Digestive Enzymes Syrup

Gripe Water Syrup

Haldi Chandan Face Wash

Placeholder

Herbal Anti Diarrhea Capsules

Herbal Baby Massage Oil

Herbal Cough Syrup

Herbal Dengue Fever Tablets

Herbal Eye Drops

Herbal Hair Oil

Herbal Hand Wash

Herbal Kidney Stone Capsules

Herbal Multivitamin Syrup

Herbal Pachak Churan

Herbal Pain Relief Roll-On

Herbal Shampoo

Immune M Caps

Immunity Booster Capsules

Immun-m Syp

Immunity Booster Syrup

Iron & Calcium Tonic Syrup

Kidney Stone Syrup

Laxative Powder

Phyto-Leuc Caps

Leucorrhoea Herbal Capsules

Liver Tonic

Liver Tonic with Silymarin Syrup

Nano Curcumin Capsules

Neem, Aloevera & Glycerin Soap

Neem, Karela, Jamun, Giloy Juice

Noni with Garcinia Juice

Onion Black Seed Oil

Pain Relief Capsule

Panch Tulsi Drops

Pancharishta Tonic

Sperm Count Increase Capsules

Syrup for Gas Ingestion

Triphala Powder (Haritaki + Bibhitaki + Amla)

Uterine Tonic

Vaginal Intimate Wash

Growth of Ayurvedic Herbal Products For PCD Franchise

The worldwide market for Ayurvedic products and medicines is around $23. 81 billion and is expected to grow at 15.06% for the next ten years. The potential for growth in this industry is very promising. Because the market is growing, Indian Ayurvedic companies are making a lot of money. Many things make people want to buy herbal products more, like increasing per capita expenditure, making more money overall, a better economy, and a positive perception. Many people in India have common health problems and are searching for natural remedies to treat them. Ayurveda is the top way to treat these diseases. More use of Herbal products in India means better healthcare facilities. 

However, there are two main groups: organized and unorganized. Additionally, there are different categories of organized Herbal products, such as healthcare products like Ayurvedic vitamins and dietary supplements, and Ayurvedic medicines. Also, another type of popular product is things you use for taking care of yourself, like products for your skin, your mouth, your hair, and fragrances. Swastik Ayurveda has good products at low prices. You can start a successful business as an Ayurvedic/herbal PCD Franchise in India.

Why Swastik Ayurveda is the Best Choice for Herbal Ayurvedic Products?

When it comes to the best Ayurvedic PCD franchise company in India, Swastik Ayurveda is the first name that comes to mind. We are a well-known company in the Ayurvedic industry in India. Swastik Ayurveda is a big company that offers herbal products. Our company has been selling top-quality Ayurvedic products since 2014. 

We have the top Ayurvedic PCD franchise in India and an herbal pharma franchise with many products like medicine for diabetes, liver disease, kidney stones, high blood pressure, blood purifier, cough, anaemia, piles, and thyroid. You can get clean and 100% natural healthcare products exclusively through us. With us, you can start your own business selling Ayurvedic products without any pressure. Our company received GMP & WHO certifications. Get in touch with Swastik Ayurveda now for the Ayurvedic PCD Franchise Company in India - 

Many different Ayurvedic products make customers happy.

Nice-looking wrapping makes people and customers interested.

Cooperation in making medicines according to strict rules and quality standards.

A company that makes Ayurvedic products and is certified by ISO.

We make Ayurvedic products that have been approved by DGCI.

Our products are approved by the Ministry of AYUSH for use in India's healthcare.

Contact Information

Name: Swastik Ayurveda

Address: Plot No-295, Phase-2 Industrial Area, Panchkula – 134113, Haryana

Contact: +91-9780917734

Email: sales5swastik@gmail.com

[govindhtech]

How Chugai Pharmaceutical Rises Drug Discovery with AI

Chugai Pharmaceutical

As one of the top pharmaceutical businesses promoting digital transformation (DX), Chugai Pharmaceutical has been named a “DX Brand” for three years running by the Tokyo Stock Exchange and the Ministry of Economy, Trade, and Industry in Japan. Additionally, in 2023, Google cloud received the DX Stocks program’s “Digital Transformation Platinum Company 2023-2025” designation. Google cloud operations and their ability to innovate in medication discovery and testing are largely dependent on digital transformation.

Right now, Google Cloud are concentrating on digitising Google cloud R&D and research and development departments. Several iterations of trial and error were engaged in the past when developing and testing new medications. Pharmaceutical corporations spend a lot of time and money on this process because it can take 15 years to make one drug. AI is helping us innovate and discover novel drugs faster.

Digital Transformation

DX stock

Many pharmaceutical companies use machine learning (ML) to develop stronger drugs and artificially create antibody therapies. One of major accomplishments, in Google cloud opinion at Chugai, is the DX stock selection. Google cloud view digital transformation as an enterprise-wide endeavour. They are spearheading significant improvements to R&D infrastructure in particular, such as developing an in-house protein structure estimation system.

To use AI to accelerate R&D, strong solutions are required. They moved Google cloud IT infrastructure to the cloud in order to achieve this. It would have taken several months and tens of millions of Japanese yen to launch any effort with Google cloud prior on-premises method. In an effort to spur further creativity, their most skilled employees including data scientists have now relocated to Google Cloud.

Google cloud started a pilot in 2022 to integrate Google Cloud with the Chugai Cloud Infrastructure (CCI), a multi-cloud infrastructure of the next generation. As part of the company’s cloud migration, they individually established and optimised infrastructures; to standardise these efforts, Google cloud implemented the CCI. As a Google cloud aim to realise their “Chugai Digital Vision 2030″ in 2020 becoming a leading innovator in healthcare solutions that use digital technology to transform society this will be essential. The three primary strategies outlined in the vision are: enhancing the digital platform; streamlining all value chains; and implementing a digital transformation for drug development.

Chugai Pharma

The primary cloud platform integration infrastructure was introduced as phase one of the CCI’s phased construction in April 2023. Google cloud are presently advancing with multi-cloud integration, including Google Cloud, and are in phase two. Simultaneously, through enhancing their functionality and operating efficiency, Google cloud are fortifying Google cloud platform infrastructure. In opinion, Google Cloud offers better ML and AI capabilities than other cloud platforms, in addition to having a stronger analytics architecture. Their goal is to promptly offer these features to users as a CCI service.

Additionally, they think that Google Cloud offers the features that Chugai Pharmaceutical drug discovery specialists are seeking. Even though they haven’t finished implementing Google Cloud, they intend to use it in the future to create and run artificial intelligence (AI) for drug development, beginning with Google subsidiary DeepMind and its 3D protein structure prediction engine, AlphaFold2. Now that AlphaFold2 is compatible with Vertex AI, Google cloud ought to be able to include it with ease.

While AlphaFold2 can estimate protein structures from sequence data with remarkable accuracy, there are still a number of implementation and resource acquisition challenges, and the CPU and GPU require a lot of resources.

They are creating Google cloud own protein structure estimate technology in order to address this. Google cloud want to build a system that any employee in the organisation can use, even if it’s still in the early phases of development, so they can quickly deduce 1,000 or more protein structures in a single day.Image credit to Google cloud

Using BigQuery for app development and data analysis

Right now Google cloud aren’t standardising Google cloud ML processes because every project is handled separately. Instead, by constantly enhancing the model with ML and BigQuery for data analysis and app development, they want to accelerate system integration and boost the value Google cloud offer to users.

The ability to easily enter and analyse data is another advantage of utilising BigQuery. Google cloud use BigQuery not only to fuel Google cloud AI for drug discovery, but also for web access analysis, application development, and future uses in other areas of Google cloud business.

Extending Tech Kobo’s use of Google Cloud

Tech Kobo, a subsidiary of Chugai Pharmaceuticals, is an internal application development team operating in a cloud environment.

Google Cloud is currently being gradually implemented throughout the entire company. Tech Kobo will eventually have the ability to use machine learning models that data scientists have put into practice on Google Cloud. There might be a chance to develop an API for Cloud Run and Cloud Functions as system integration gets more smooth, allowing a wider user base to freely utilise these models.

Tech Kobo is to leverage Google Cloud for the development of its mobile applications. Simultaneously, the company will leverage Firebase, a backend cloud computing stack from Google, to construct its mobile backend as a service (mBaaS).

Google Cloud is more than simply an infrastructure supplier. Additionally, it helps their team members hone their talents and provide better results. With an eye towards the future, Google cloud seek to advance and mould the field of drug discovery by absorbing information and expertise from many global marketplaces.

Read more on Govindhtech.com

[osvftwz]

Top Four Requirements A 3PL Company Should Meet Before Export Pharmaceuticals To India

Pharmacies may be challenging to ship for a lot of carriers and Export pharmaceuticals to India. Shipments of pharmaceuticals are intricate processes that require precision and close attention to detail to avoid expensive errors. Over the past few decades, the pharmaceutical industry has made great strides towards producing medications for particular people and rare disorders. These specialty pharmaceutical drugs are available in many different formats.

One class of shipping medicines is biological. Tissues, allergies, DNA, blood, and vaccines are among them. The demand for the COVID-19 vaccination has caused a dramatic surge in the popularity of biologics. In addition, over-the-counter pharmaceuticals such as supplements, minerals, and vitamins are available. There are three forms of pharmaceutical products: liquid, ointment, and solid.

Fundamentals of transportation for prescription drugs

Because of the conditions under which pharmaceuticals must be stored and the need for prompt delivery, carriers prefer shipping via road. Even though flying is the fastest way to travel, especially over long distances, its popularity has drastically decreased due to a lack of openness and uniform standards. In the event that expedited delivery of medications is required, refrigerated containers can be carried via train or sea. A large number of pharmaceutical businesses choose to ship by sea due to the efficient supply chain.

It is essential to monitor the regulated temperature and humidity levels in the air while delivering medications. It is imperative that drugs and ice packs never come into contact. They have to be picked up right away from the manufacturer. The whole journey, including the duration and any temperature variations inside the container, should be documented. The top transportation companies account for everything that may go wrong, such as delays and broken air conditioning systems.

Fundamental arrangements for the shipping of pharmaceuticals

Equipment on Vehicles

Make sure delivery vehicles for pharmaceuticals are equipped with the appropriate construction and tools. For example, safety measures and the necessary temperature controls must be installed in trailers.

Transporting Drugs Businesses

Export pharmaceuticals to India companies must completely clean the cargo compartment of the caravan to prevent cross-contamination. Equipment for monitoring and controlling temperature must also have regular maintenance and inspections in order to continue operating as intended.

Education and training 

Individuals who directly distribute drugs need to possess the necessary abilities. This training must be documented.

Labelling 

Each pharmaceutical shipment container for export pharmaceuticals to India must have a clearly visible label. Documentation Training and transportation-related records need to be maintained and properly archived.

Transport-ready pharmaceutical packaging

Shipping pharmaceutical products also requires suitable and careful packaging. Products may be protected by these heat packs against a variety of environmental factors, such as humidity, UV light, and temperature fluctuations. Temperature-controlled shipping is necessary for seven out of ten drugs; special handling is required for transporting natural items including tissues, regeneration agents, and haemoglobin. Pharma items are often stored in thermos containers, which are cryogenic containers that can resist temperatures as low as -150 degrees Celsius.

Pharmaceutical products may be sent by some carriers utilising heat pallets. These unique pallets provide an extra degree of protection. Pallet covers with thermal insulation can help prevent damage to pharmaceutical supplies. It's also important to store containers and boxes as effectively as possible. Moving as little as possible while conveying a large quantity of products is the goal. Medication is often transported in extremely fragile condition. If any of the pharmaceutical items are damaged, there's a good chance they won't be able to be used or sold.

Temperature-regulated transportation

Time starts to elapse before a pharmaceutical's expiration date once it is manufactured. Anticipating deterioration is the goal of refrigerated medicinal items. The refrigerator trailers can function without the assistance of a vehicle thanks to their power source. It allows its refrigeration system to function. Whether delivered by vehicle or by another means, it is designed to guarantee that the pharmaceutical items maintain their coolness. 

Adhere to the refrigerant flow.

Transportation with temperature control is not a new concept. The concept originated in the 1840s when ice and bitter cold were used to facilitate train-based cold chain operations.

Carrier instructions may cover a variety of topics, such as driver guidelines, confidentiality, safe cargo handling, incident reporting, cargo tracking, and required reaction times. The transporter usually signs contracts stating these terms when a customer requests to work with them.

A vital link in the supply chain is the driver for export pharmaceuticals to India. A motorist must pay close attention to detail while transporting valuable items like prescription drugs. Drivers should ensure safety when delivering pharmaceuticals by minimising the amount of time the vehicle is left unattended and removing unnecessary stops. 

Drivers must also get proper training. For the cold chain logistics procedure during export pharmaceuticals to India, drivers must have specialised training in addition to being knowledgeable about traffic rules. The driver must be familiar with the mechanics of refrigeration trucks. Always keep the vehicle's temperature at the proper level, driver. The following suggestions might lessen the hazards associated with drivers and medical firms transporting drugs.

Protection from theft

It is imperative to have trustworthy theft prevention systems installed if you are shipping pharmaceuticals. Not only are the products expensive, but there's a chance they may be stolen and end up in the hands of thieves, which could cause major problems.

It is the shipper's responsibility to prevent theft in some cases, and the carrier's responsibility in others.  A crucial safety precaution that shippers may take is to pack properly. Potential robbers may be drawn in by packaging that makes it obvious what is inside. If the items are not mentioned on the packaging, it becomes less appealing.

Enhancing safety and reducing the likelihood of theft involves the following solutions: constant GPS tracking; driver contact throughout the pharmaceutical shipment; a team of drivers; chaperone services; and a direct route free of diversions. One of the greatest ways to stop pharmaceutical supplies from being stolen is to have an open discussion with your delivery partner. Letting them know about the items you are shipping and the level of protection required is the best course of action. The best solution to meet your demands in that circumstance will subsequently be able to be offered by your shipping partner.

What to Look for When Choosing a Pharmaceutical 3PL as a Partner

These four essential requirements are what your 3PL needs to provide for dependable pharmaceutical shipping.

1. PHARMACOLOGICAL INDUSTRY EXPERIENCE

Shipments of other goods are not the same as those of medications. To guarantee the integrity of the product, ambient temperature, humidity, and light levels must be constantly observed. Timeliness and security are maintained with the use of precise documentation and secure containers. Working with a seasoned 3PL is the greatest approach to make sure your demands are satisfied since you need to have complete faith that your items are in good hands and will reach their destination. 

2. A GRANTING NETWORK WITHIN THE INDUSTRY

In the modern supply chain, disruptions are frequent. It should be possible for your logistics partner to predict any problems and take action before they affect your cargo since they should keep a close eye on the industry for export pharmaceuticals to India. Onnsynex has a large network of carriers with comparable skills that we work with to solve issues fast and prevent delays so that your critical cargo reaches its destination on time. 

3. AVAILABLE COMMUNICATION

Any healthy relationship starts with communication. Because so much is at risk while carrying sensitive items, this competence becomes even more crucial. To ensure that you always know where your items are and exactly what to expect, choose a 3PL for export pharmaceuticals to India that places a high value on open and transparent communication. Do not accept anything less from them; it is their responsibility to soothe your concerns. 

4. A CHOIRBOOK TO DIRECT THEIR SELECTIONS

Success in logistics is a carefully planned process driven by expertise and in-depth knowledge of the sector, not by chance. There are certain handling and packing requirements for every kind of pharmaceutical cargo or item. To make sure your items receive the right care and handling, your 3PL partner should be aware of these demands and have expertise working with a variety of materials and products. Consistency, which a playbook offers, makes processes dependable, repeatable, and long-lasting. Technology is necessary to direct these procedures. It links the chain from the laboratory to the ultimate destination of your cargo, removes administrative mistakes, and allows real-time visibility into every activity. 

The Benefits of Onnsynex

Being a reliable intermediary between your laboratory and your clients is our goal at Onnsynex. With the help of cutting-edge technology and decades of experience, we offer pharmaceutical transportation logistics of the future. Inform us of your transportation requirements, and we will provide reliable, dependable, and safe solutions. Get a quotation right now, or schedule a call to find out more. 

[irenepharma]

Best PCD Company in Gujarat - Irene Pharma

PCD Pharma in Gujarat

Irene Pharma is the best PCD company in Gujarat. Main focus of our pharma organizaiton lies on solving all health ailments that people suffer from. The company deals with a widesr range of pharmaceutical medicines like; antibiotic medicines, pain killer medicines, dental range, dermataology products, ayurvdeic products, face wash, nutraceutical supplements, pediatric range, nephrology medicines, and general range as well.

[michaelitservices]

Top 10 Pharmaceutical Companies in 2023: How COVID-19 Reshaped the Industry

See how COVID-19 impacted the pharmaceutical industry in 2023. This article explores the top ten pharma companies by revenue, including how established players fared and how new product approvals influenced rankings.

In the dynamic landscape of the pharmaceutical industry, certain companies stand out as leaders, driving innovation, and shaping the future of healthcare. As we delve into the year 2023, let's take a closer look at the top ten pharmaceutical giants that continue to influence the global market.

1. Pfizer

With a rich history of breakthroughs, Pfizer maintains its position as a powerhouse in the pharmaceutical world. From vaccines to therapeutics, the company's innovative portfolio remains at the forefront of healthcare advancements.

2. Roche

Renowned for its expertise in oncology and diagnostics, Roche continues to make strides in personalized medicine. Through strategic partnerships and cutting-edge research, the company remains a key player in cancer treatment and detection.

3. Johnson & Johnson

As a diversified healthcare conglomerate, Johnson & Johnson boasts a robust portfolio spanning pharmaceuticals, medical devices, and consumer health products. With a commitment to innovation and sustainability, the company maintains its status as a global leader.

4. Novartis

Driven by a mission to reimagine medicine, Novartis focuses on developing transformative therapies for a range of diseases. From innovative gene therapies to breakthrough treatments, the company remains a frontrunner in healthcare innovation.

5. Merck & Co.

Merck & Co. continues to make significant contributions to global health with its portfolio of vaccines, pharmaceuticals, and animal health products. Through strategic acquisitions and research collaborations, the company remains a driving force in the fight against infectious diseases and chronic conditions.

6. AstraZeneca

With a dedication to advancing science and delivering life-changing medicines, AstraZeneca remains a key player in the pharmaceutical landscape. From cardiovascular treatments to respiratory therapies, the company's diverse portfolio addresses some of the most pressing healthcare challenges.

7. GlaxoSmithKline

Known for its commitment to innovation and global health initiatives, GlaxoSmithKline continues to make a positive impact on patient care. Through strategic investments in research and development, the company remains at the forefront of vaccine development and infectious disease management.

[cooperpharmalimited]

Top 10 Pharmaceutical Third Party Manufacturing Company In India

As of my last update in January 2022, it's important to note that the landscape of pharmaceutical companies can change rapidly due to various factors such as mergers, acquisitions, and shifts in market dynamics. COOPER PHARMA LIMITED

However, here are ten prominent pharmaceutical third-party manufacturing companies in India, which were recognized for their capabilities, reliability, and quality:

Aurobindo Pharma Ltd.

Sun Pharmaceutical Industries Ltd.

Cipla Ltd.

Lupin Limited

Cadila Healthcare Ltd. (Zydus Cadila)

Alkem Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

Torrent Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

Biocon Ltd.

Please note that this list is not exhaustive, and there are many other reputable pharmaceutical companies in India that offer third-party manufacturing services. It's essential to conduct thorough research and due diligence to select the most suitable partner based on your specific requirements and criteria. Additionally, the rankings and reputations of these companies may have changed since my last update, so I recommend verifying their current status and capabilities.

Contact US: -

2nd Floor Plot No-5, Nidhi Plaza-II, LSC Gulabi Bagh, Near Shakti Nagar Railway Bridge Delhi-52 India 24X7 Customer Care: +91-9315951001 Phone: +91-11-23653537, 23653404 Email: cooperpharma@hotmail.com

[swisschem]

What is the minimum investment required to start a PCD Pharma Franchise?

The pharmaceutical industry is growing quickly and is one of the fastest-growing industries in the world. The PCD Pharma franchise is a good opportunity for people to start their own business in the pharmaceutical industry without spending a lot of money. Swisschem Healthcare, a top PCD Pharma company, is looking for people who want to start a business in all of India. Becoming a pharma franchise owner for a PCD company can be expensive, and the cost depends on the size of the business location and the range of products. Usually, you should invest Rs 40,000 to Rs 50,000. Here are some places where you should put your money: You will need to rent or buy a suitable building. The size of your building will be based on how big your business is.

Investment Required for PCD Pharma Franchise

The investment cost depends on various factors, all these factors create a form of business module.

Pharma Franchise Cost in India - The cost of owning a PCD Pharma Franchise in India depends on the Pharma Franchise Cost. This is the first fee that the franchisee pays to the company to operate under their brand. Depending on how well-known the brand is, how good its reputation is, and how exclusive its territory is, the fee can be anywhere from tens of thousands to hundreds of thousands of Indian rupees. Owning a PCD Pharma Franchise in India can cost between RS 40,000 to 50,000, depending on the type of pharmaceutical business you have.

Setup and Infrastructure Cost - These are the expenses for getting an office or store ready to use. These expenses can include renting a space, fixing it up, decorating the inside, installing things like lights and furniture, and buying equipment. The size and where your building is will also change how much it costs to set up and have the right equipment.

Legal Complications & Licensing- Pharmaceutical companies must have different licenses and permits to operate legally. These licenses are for drugs, taxes, food and drug regulations, and others. The number of licenses needed will be based on the country and area where the business is located.

Inventory cost - The price of inventory depends on how much and what kind of medicine you want to keep in stock. It is important to have many different types of medicines in stock to help all kinds of customers. The price of inventory can change a lot. Before you hire and train employees, think about how much it will cost. This will include how much money you will make, the extra things you get, how you will be trained, and if you will need a pharmacist or other skilled people to help you with your work.

Marketing - How much money should you spend on advertising to promote your brand and get customers? The cost of advertising can change based on who you are trying to reach and how many other businesses are trying to reach them too. You can use online ads, regular marketing methods, marketing materials, and local healthcare events to make more people know about your brand

[wellonapharmaindia]

Role of Indian Pharmaceutical Companies

From the past three decades, the pharmaceutical industry has been performing well. Hence, more and more entrepreneurs are getting attracted to it.

What are the strengths of the pharma industry if we think about the Indian industry in particular? They are clinical research, contract research and manufacturing, and research and development of vaccines.

Many multinational industries prefer India to outsource their activities and contribute the sector to perform better.

All these factors indicate that the future is bright for Indian pharmaceutical companies.

Some facts

It is not merely an assumption, but a fact substantiated by statistics.

The Indian pharma industry is one of the largest in the world.

It is 4th in the world by ranking based on the volume of sales.

The estimated worth is more than 6 Billion USD.

The industry is growing by more than 13 percent every year.

The domestic demand for bulk drugs fulfilled by the Indian pharma industry is around 70 percent.

Not just finished goods, but the Indian pharmaceutical industry is one of the largest producers of Active Pharmaceutical Ingredients or API

The sector is the leader of scientific research-based industries.

Out of the total exports, 45% is contributed by bulk drugs and 55% by formulations.

The sector has a broad spectrum of industries of all sizes and scale. From small scale to medium-scaled and large-scaled players; the whole range is there.

The saga of growth

If you consider the rate of growth as on date, then it is expected that the industry will have worth more than 45 Billion USD by the next decade. The sector is going to be one of the Top Ten clubs of pharma-based markets in the world.

As the medical infrastructure in India is increasing, the health services will be transformed and boost the growth of the industry further.

Foreign investment will be attracted further by the large concentration of multinational players. Economists predict pharma as one of the major sectors that will attract FDI (Foreign Direct Investment) in the coming years.

Due to Contract Research and Manufacturing Services or CRAMS, there will be a high thrust to the business. The estimated value is 900 Million USD, which is quite impressive.

The low cost of production and products of international standards are the two big contributors to business growth.

Are these factors not indicating a phenomenal growth path and incredible business opportunities for pharma players? Indeed, the picture is very much encouraging.